Finnish medtech startup Fimmic has raised €5 million for its AI tissue diagnostics platform. The round was led by Ascend Capital Partners with participation from ACME Investments and STO-Rahoitus.

Fimmic develops the WebMicroscope platform for AI-based image analysis of tissue diagnostics, which boosts the speed and accuracy of diagnoses. The company was spin-out of the Finnish Institute for Molecular Medicine at the University of Helsinki.

“Our AI algorithms have been successfully used in various applications ranging from cancer research to drug development projects on Parkinson’s disease and liver diseases,” said CEO Kaisa Helminen.

The results have been promising so far, she added, and with this new capital the company plans to launch in the US market and grow its team.

Comments are closed.